Autopsy report · NCT04637009

A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms

“termination due to portfolio prioritization”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 2 years 2 months before it stopped.
• 20 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Astex Pharmaceuticals, Inc.

Sponsor type

Industry

Conditions

Acute Myeloid Leukemia; Myeloproliferative Neoplasm; Myelodysplastic/Myeloproliferative Neoplasm

Interventions

TAS1553

Participants

20

Sites

10

Countries

Canada, United States

Trials that died the same way

• Safety Study of SEA-CD40 in Cancer Patients
  “Study closed due to portfolio prioritization” (69% match in meaning)
• A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
  “Portfolio re-prioritization” (67% match in meaning)
• Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients
  “Pfizer made a business-related decision on 04May2017 to terminate study based on change in portfolio prioritization, and is not due to safety or efficacy.” (64% match in meaning)
• HPV16 E6 TCR T Cells for Cervical Carcinoma
  “Study terminated due to strategic portfolio decision to reallocate resources to higher-priority programs” (61% match in meaning)
• Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors
  “Terminated due to Oncorus portfolio reprioritization” (59% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.